Literature DB >> 18191875

CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies.

Fredrik Boström1, Oskar Hansson, Lars Gerhardsson, Thomas Lundh, Lennart Minthon, Erik Stomrud, Henrik Zetterberg, Elisabet Londos.   

Abstract

Accumulating evidence implicates a role for altered metal homeostasis in the pathogenesis of neurodegenerative disorders such as Alzheimer's disease (AD). However, few investigations have addressed this issue in dementia with Lewy bodies (DLB). The aim of the present study was to investigate metal concentrations in cerebrospinal fluid (CSF) and plasma from patients with DLB and other neurodegenerative disorders. To that end, CSF and plasma samples were collected from 29 patients with DLB, 174 patients with AD, 90 patients with AD with minor vascular components, and 51 healthy volunteers. Total concentrations of Mg, Ca, Mn, Fe, Cu, Zn, Rb, Sr, and Cs were determined using mass spectrometry. Patients with DLB had elevated Ca and Mg levels in CSF and Mg levels in plasma as compared to all other groups (p<0.001). Furthermore, a combination of CSF-Mg and CSF-Ca could distinguish DLB from AD with a sensitivity of 93% and a specificity of 85%. Cu levels in both CSF and plasma tended to be higher in DLB compared to the other groups, but these trends failed to reach significance after correction for multiple comparisons. Mn, Fe, Zn, Rb, and Sr concentration in CSF or plasma were similar in all groups. The observed elevations of CSF-Mg, CSF-Ca and CSF-Cu may contribute to or be associated with the neurodegenerative process in DLB. Furthermore, determination of CSF-Mg and CSF-Ca concentration may be a valuable tool in distinguishing DLB from AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18191875     DOI: 10.1016/j.neurobiolaging.2007.10.018

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  9 in total

Review 1.  Metals in Alzheimer's and Parkinson's Disease: Relevance to Dementia with Lewy Bodies.

Authors:  Erin J McAllum; David I Finkelstein
Journal:  J Mol Neurosci       Date:  2016-08-08       Impact factor: 3.444

2.  Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders.

Authors:  Pashtun Shahim; Kaj Blennow; Per Johansson; Johan Svensson; Simone Lista; Harald Hampel; Leif Christer Andersson; Henrik Zetterberg
Journal:  Neuromolecular Med       Date:  2016-09-19       Impact factor: 3.843

3.  Cerebrospinal fluid biomarkers for dementia with lewy bodies.

Authors:  Elizabeta B Mukaetova-Ladinska; Rachael Monteith; Elaine K Perry
Journal:  Int J Alzheimers Dis       Date:  2010-10-17

Review 4.  Oxidative Stress and Its Clinical Applications in Dementia.

Authors:  Peizhong Mao
Journal:  J Neurodegener Dis       Date:  2012-08-30

Review 5.  Biomarkers in biological fluids for dementia with Lewy bodies.

Authors:  Sebastian Schade; Brit Mollenhauer
Journal:  Alzheimers Res Ther       Date:  2014-10-16       Impact factor: 6.982

Review 6.  The Role of Magnesium in Neurological Disorders.

Authors:  Anna E Kirkland; Gabrielle L Sarlo; Kathleen F Holton
Journal:  Nutrients       Date:  2018-06-06       Impact factor: 5.717

7.  The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin.

Authors:  Line K Skaanning; Angelo Santoro; Thomas Skamris; Jacob Hertz Martinsen; Anna Maria D'Ursi; Saskia Bucciarelli; Bente Vestergaard; Katrine Bugge; Annette Eva Langkilde; Birthe B Kragelund
Journal:  Biomolecules       Date:  2020-08-16

8.  Association of Circulating Magnesium Levels in Patients With Alzheimer's Disease From 1991 to 2021: A Systematic Review and Meta-Analysis.

Authors:  Ke Du; Xi Zheng; Zi-Tai Ma; Jun-Ya Lv; Wen-Juan Jiang; Ming-Yan Liu
Journal:  Front Aging Neurosci       Date:  2022-01-10       Impact factor: 5.750

Review 9.  Zinc in Cognitive Impairment and Aging.

Authors:  Ruize Sun; Jue Wang; Juan Feng; Bin Cao
Journal:  Biomolecules       Date:  2022-07-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.